During Thursday’s Current trade, Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH), lost -0.49% to $106.35.
Zimmer Biomet Holdings, Inc. (ZBH) stated financial results for the quarter ended June 30, 2015. The Company stated second quarter net sales of $1.17 billion, a decrease of 1.3% stated and an enhance of 5.7% constant currency contrast to the second quarter of 2014. Attained revenue from Biomet amounted to $60 million, a contribution of 5.0% of the constant currency growth rate. Standalone Zimmer recorded constant currency growth in the quarter of 0.7%. Stated net loss per share for the quarter was $(0.91) and adjusted earnings per share were $1.59, an enhance of 0.6% over the preceding year period.
Zimmer Biomet Holdings, Inc., together with its auxiliaries, designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. It offers orthopaedic reconstructive devices that restore function lost due to disease or trauma in joints comprising knees, hips, shoulders, and elbows; dental reconstructive implants, which restore function and aesthetics in patients who have lost teeth due to trauma or disease; spinal devices that are utilized by orthopedic surgeons and neurosurgeons for the treatment of degenerative diseases, deformities, and trauma in various regions of the spine; and trauma devices used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process.
Shares of OHR Pharmaceutical Inc (NASDAQ:OHRP), declined -3.75% to $2.95, during its current trading session.
Ohr Pharmaceutical, Inc. (OHRP), an ophthalmology research and development company, recently declared positive final results from a Phase II investigator sponsored clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution) in patients with macular edema secondary to branch (BRVO) and central retinal vein occlusion (CRVO). The results demonstrated that, following an initial 10 week combination therapy treatment period, patients who continued to receive a combination of topical OHR-102 BID plus Lucentis(R) achieved greater visual acuity gains than the control group who received Lucentis alone. At week 38, the mean gain in visual acuity from baseline for patients randomized (at week 10) to treatment with OHR-102 + Lucentis PRN was +27.8 letters contrast with +23.3 for patients randomized to treatment with Lucentis plus PRN alone (control group), a clinically meaningful difference of +4.5 letters. The data were presented by John Wroblewski, MD, a retina specialist at Cumberland Valley Retina Consultants on Saturday, July 11 at the 2015 Annual Meeting of the American Society of Retina Specialists (ASRS) in Vienna, Austria.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
F.N.B. Corp (NYSE:FNB), during its Thursday’s current trading session decreased -0.65% to $13.74.
F.N.B. Corporation (FNB) declared that its Board of Directors declared a quarterly cash dividend of $18.13 per share (equivalent to $0.45325 per depositary share or 1/40th interest per share) on F.N.B. Corporation’s Non-Cumulative Perpetual Preferred Stock, Series E (NYSE:FNB PR E). The dividend is payable on August 17, 2015, to shareholders of record as of the close of business on July 31, 2015.
F.N.B. Corporation, a financial holding company, provides various financial services to consumers, corporations, governments, and small- to medium-sized businesses primarily in Pennsylvania, eastern Ohio, and northern West Virginia. It operates through four segments: Community Banking, Wealth Administration, Insurance, and Consumer Finance. The Community Banking segment offers various services, counting commercial and individual demand, savings, and time deposit accounts; and commercial, mortgage, and individual installment loans.
Finally, Infinera Corp. (NASDAQ:INFN), decreased -1.30%, to $22.69.
Infinera Corporation ( INFN), provider of Intelligent Transport Networks, released financial results for the second quarter of 2015 ended June 27, 2015.
Revenue for the quarter was $207.3 million contrast to $186.9 million in the first quarter of 2015 and $165.4 million in the second quarter of 2014.
GAAP gross margin for the quarter was 46.7% contrast to 47.2% in the first quarter of 2015 and 42.5% in the second quarter of 2014. GAAP operating margin for the quarter was 8.0% contrast to an operating margin of 8.1% in the first quarter of 2015 and an operating margin of 4.9% in the second quarter of 2014.
GAAP net income for the quarter was $17.9 million, or $0.13 per diluted share, contrast to $12.4 million, or $0.09 per diluted share, in the first quarter of 2015, and $4.8 million, or $0.04 per diluted share, in the second quarter of 2014.
Infinera Corporation provides optical transport networking equipment, software, and services for telecommunications service providers, Internet content providers, cable operators, wholesale and enterprise carriers, research and education institutions, and government entities worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.